Drug tapering noninferior to treatment continuation for rheumatoid arthritis with low disease activity
· Medical Xpressby Elana Gotkine
edited by Gaby Clark, reviewed by Andrew Zinin
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
reputable news agency
proofread
The GIST Add to Preferred Sources
For patients with rheumatoid arthritis (RA) with sustained low disease activity (LDA), structured tapering of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) is noninferior to treatment continuation for maintaining disease control over 24 weeks, according to a study published online Oct. 6 in Arthritis & Rheumatology.
Dong-Jin Park, MD, Ph.D., from Chonnam National University Medical School and Hospital in Gwangju, South Korea, and colleagues examined the efficacy and safety of a structured b/tsDMARD tapering strategy in patients with RA who had achieved sustained LDA in a 24-week, randomized, noninferiority trial. Patients with RA receiving stable-dose b/tsDMARDs and maintaining Disease Activity Score-28 using erythrocyte sedimentation rate-defined LDA for at least six months were randomly assigned to stepwise dose tapering or dose continuation (171 and 177 patients, respectively).
The researchers found that LDA was maintained in 89.6% and 88.2% of patients in the continuation and tapering groups, respectively, in the per-protocol population, with a risk difference of −1.43 percentage points (95% confidence interval, −8.9 to 5.23), meeting the noninferiority criterion. In the full analysis set, findings were similar. For most patients experiencing disease worsening, LDA was regained after protocol-guided treatment re-escalation during follow-up. Comparable secondary outcomes were seen between the groups, although some disease activity measures favored continuation. Adverse events occurred infrequently in both groups.
"With careful patient selection, close monitoring and timely treatment re-escalation when needed, dose tapering may reduce treatment burden while maintaining disease control and health-related quality of life," the authors write.
More information
Dong‐Jin Park et al., Outcomes of Tapering Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Multicenter Randomized Noninferiority Trial, Arthritis & Rheumatology (2026). DOI: 10.1002/art.70363
Key medical concepts
Clinical categories
RheumatologyClinical pharmacology Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
© 2026 HealthDay. All rights reserved.
Citation: Drug tapering noninferior to treatment continuation for rheumatoid arthritis with low disease activity (2026, October 13) retrieved 14 October 2026 from https://medicalxpress.com/news/2026-10-drug-tapering-noninferior-treatment-rheumatoid.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.